AVB-500, a receptor tyrosine kinase AXL inhibitor, improves response to olaparib in uterine serous cancer.

被引：0
|
作者：
Toboni, Michael D. [1 ]
Mullen, Mary [1 ]
Tankou, Jo'an [1 ]
Noia, Hollie [1 ]
Oplt, Alyssa [1 ]
Wilke, Daniel [1 ]
Khabele, Dineo [1 ]
Kuroki, Lindsay [1 ]
Hagemann, Andrea [1 ]
McCourt, Carolyn [1 ]
Thaker, Premal [1 ]
Mutch, David [1 ]
Powell, Matthew [1 ]
Fuh, Katherine [1 ]
机构：
[1] Washington Univ, St Louis, MO 63110 USA
来源：
CLINICAL CANCER RESEARCH | 2021年 / 27卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO047
引用
收藏
页数：1
相关论文
共 50 条
  • [1] AVB-500, a receptor tyrosine kinase AXL inhibitor, in combination with olaparib improves response in uterine serous cancer
    Toboni, Michael
    Mullen, Mary
    Tankou, Joan
    Noia, Hollie
    Oplt, Alyssa
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolyn
    Thaker, Premal
    Mutch, David
    Khabele, Dineo
    Powell, Matthew
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S96 - S97
  • [2] Improving response to olaparib in uterine serous cancer through treatment with AVB500, a receptor tyrosine kinase AXL inhibitor
    Toboni, M. D.
    Mullen, M. M.
    Tankou, J. I.
    Noia, H.
    Oplt, A.
    Wilke, D.
    Cannon, P.
    Kuroki, L. M.
    Hagemann, A. R.
    McCourt, C. K.
    Thaker, P. H.
    Mutch, D. G.
    Powell, M. A.
    Fuh, K. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 224 - 224
  • [3] Effect of inducing HR deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor, on response to olaparib in uterine serous cancer.
    Toboni, Michael Driscoll
    Blachut, Barbara
    Mullen, Mary M.
    Tankou, Jo'an
    Noia, Hollie M.
    Oplt, Alyssa
    Wilke, Danny
    Kuroki, Lindsay M.
    Hagemann, Andrea R.
    McCourt, Carolyn K.
    Thaker, Premal H.
    Mutch, David Gardner
    Powell, Matthew A.
    Fuh, Katherine Cynthia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Inducing homologous recombination deficiency in uterine serous cancer (USC) using AVB-500, a receptor tyrosine kinase AXL inhibitor.
    Toboni, Michael D.
    Blachut, Barbara
    Lomonosova, Elena
    Khabele, Dineo
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolyn
    Thaker, Premal
    Mutch, David
    Powell, Matthew
    Fuh, Katherine
    CLINICAL CANCER RESEARCH, 2021, 27 (03)
  • [5] AVB-S6-500, a receptor tyrosine kinase AXL inhibitor, improves the therapeutic efficacy of trastuzumab in uterine serous cancers
    Tankou, Joan
    Oplt, Alyssa
    Toboni, Michael
    Bruce, Shaina
    Noia, Hollie
    Wilke, Danny
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolyn
    Thaker, Premal
    Mutch, David
    Powell, Matthew
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S148 - S148
  • [6] AVB-S6-500, a Receptor Tyrosine Kinase AXL Inhibitor, Improves the Therapeutic Efficacy of Trastuzumab in Uterine Serous Cancers
    Tankou, Jo'an Isabelle
    Oplt, Alyssa
    Toboni, Michael D.
    Bruce, Shaina F.
    Noia, Hollie
    Wilke, Danny
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolynn
    Thaker, Premal
    Khabele, Dineo
    Mutch, David
    Powell, Matthew
    Fuh, Katherine
    REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 231 - 231
  • [7] Inducing homologous recombination deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor in uterine serous cancer (USC)
    Toboni, Michael
    Blachut, Barbara
    Lomonosova, Elena
    Kuroki, Lindsay
    McCourt, Carolyn
    Hagemann, Andrea
    Thaker, Premal
    Mutch, David
    Khabele, Dineo
    Powell, Matthew
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S189 - S190
  • [8] AVB-500, a selective inhibitor of GAS6-AXL, in combination with paclitaxel alters uterine serous cancer cell metabolism
    Bruce, Shaina
    Cho, Kevin
    Lomonosova, Elena
    Noia, Hollie
    Stock, Elizabeth
    Khabele, Dineo
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolyn
    Thaker, Premal
    Mutch, David
    Powell, Matthew
    Patti, Gary
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S97 - S97
  • [9] AVB500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab compared to bevacizumab alone in uterine serous cancer mouse model
    Toboni, M. D.
    Tankou, J. I.
    Mullen, M. M.
    Oplt, A.
    Noia, H.
    Cannon, P.
    Kuroki, L. M.
    Hagemann, A. R.
    McCourt, C. K.
    Thaker, P. H.
    Mutch, D. G.
    Powell, M. A.
    Fuh, K. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 77 - 77
  • [10] AVB-500, a selective inhibitor of GAS6-AXL, shows improved therapeutic efficacy in combination with paclitaxel in uterine serous carcinoma
    Bruce, Shaina
    Noia, Hollie
    Lomonosova, Elena
    Oplt, Alyssa
    Stock, Elizabeth
    Khabele, Dineo
    Hagemann, Andrea
    Kuroki, Lindsay
    McCourt, Carolyn
    Thaker, Premal
    Powell, Matthew
    Mutch, David
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S97 - S98
12345